Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 7/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | YAP1 | P46937 | 1/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17010488 | 1.00 | ALDH1A1 (0.37) | ALDH1A1HTTTDP1ROCK2HPGD | |
| SCHEMBL17010487 | 1.00 | ALDH1A1 (0.37) | ALDH1A1HTTTDP1ROCK2HPGD | |
| SCHEMBL17010503 | 0.87 | IDH1 (0.39) | ALDH1A1HTTTDP1HPGDTSHR | |
| SCHEMBL17010514 | 0.87 | IDH1 (0.39) | ALDH1A1HTTTDP1HPGDTSHR | |
| SCHEMBL17010506 | 0.87 | IDH1 (0.39) | ALDH1A1HTTTDP1HPGDTSHR | |
| SCHEMBL17010516 | 0.87 | IDH1 (0.39) | ALDH1A1HTTTDP1HPGDTSHR | |
| SCHEMBL17010504 | 0.87 | IDH1 (0.39) | ALDH1A1HTTTDP1HPGDTSHR | |
| SCHEMBL17009701 | 0.86 | GAA (0.43) | ALDH1A1HTTTDP1IDH1KDM4E | |
| SCHEMBL17009704 | 0.86 | GAA (0.43) | ALDH1A1HTTTDP1IDH1KDM4E | |
| SCHEMBL17009707 | 0.86 | GAA (0.43) | ALDH1A1HTTTDP1IDH1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3105210-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| US-9951027-B2 | Benzimidazol-2-amines as MIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9951027-B2 | Benzimidazol-2-amines as MIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9951027-B2 | Benzimidazol-2-amines as MIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-20170197922-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2017-07-13 | — | — | US | disclosed |
| US-20170197922-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2017-07-13 | — | — | US | disclosed |
| US-20170197922-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2017-07-13 | — | — | US | disclosed |
| EP-3105210-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-21 | — | — | EP | disclosed |
| CN-105980365-A | Benzimidazol-2-amines as mIDH1 inhibitors | 拜耳医药股份公司 | 2016-09-28 | — | — | CN | disclosed |
| WO-2015121209-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015121209-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197922-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | HRH1, HRH2, HRH3 | ALDH1A1 706/4885HTT 1398/4885TDP1 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.